Abstract
We evaluated the effectiveness of sildenafil citrate on lower urinary system symptoms (LUTS) by using symptom score scales. We also evaluated whether or not the presence of asymptomatic inflammatory prostatitis had an effect on the alteration in the symptom scores. A total of 36 male patients were included in the study. For all the cases, ‘International Prostate Symptom Score’ (IPSS), ‘National Health Institute Chronic Prostatitis Symptom Index’ (NIH-CPSI) and ‘International Index of Erectile Function’ (IIEF-5) were investigated and the scores were calculated in the first visit. Sildenafil citrate was given for 30 days and at the second visit IPSS, NIH-CPSI and IIEF-5 scores were once more analyzed. Afterwards, the alterations of the scores between visits were statistically compared. Mean age of the 36 cases included in the study was 59.03±1.35. When the alterations in parameters of first visit and second visit were evaluated, we found a statistically significant increase in IIEF-5 and a statistically significant decrease in IPSS, IPSS-QOL (Quality of Life). In addition, when the cases were divided into two groups with and without asymptomatic inflammatory prostatitis, in the cases with asymptomatic inflammatory prostatitis, sildenafil citrate caused improvement only in ED, but had no effect on LUTS. Sildenafil citrate use in cases with LUTS and ED has an improving effect on LUTS as well as ED. However, in cases with asymptomatic inflammatory prostatitis, sildenafil citrate did not lead to an improvement in LUTS.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 8 print issues and online access
$259.00 per year
only $32.38 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Rosen R, Altwein J, Boyle P, Kirby RS, Lukacs B, Meuleman E et al. Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7). Eur Urol 2003; 44: 637–649.
Costabile RA, Steers WD . How can we best characterize the relationship between erectile dysfunction and benign prostatic hyperplasia? J Sex Med 2006; 3: 676–681.
Wang C . Phosphodiesterase-5 inhibitors and benign prostatic hyperplasia. Curr Opin Urol 2010; 20: 49–54.
Carson CC . Combination of phosphodiesterase-5 inhibitors and alfa-blockers in patients with benign prostatic hyperplasia: treatments of lower urinary tract symptoms, erectile dysfunction, or both? BJU Int 2006; 97: 39–43.
Marszalek M, Wehrberger C, Hochreiter W, Temml C, Madersbacher S . Symptoms suggestive of chronic pelvic pain syndrome in an urban population: prevalence and associations with lower urinary tract symptoms and erectile function. J Urol 2007; 177: 1815–1819.
Müller A, Mulhall JP . Sexual dysfunction in the patient with prostatitis. Curr Opin Urol 2005; 15: 404–409.
Liang CZ, Zhang XJ, Hao ZY, Shi HQ, Wang KX . Prevalence of sexual dysfunction in Chinese men with chronic prostatitis. BJU Int 2004; 93: 568–570.
Bushman W . Etiology, epidemiology, and natural history of benign prostatic hyperplasia. Urol Clin North Am 2009; 36: 403–415.
Krieger JN, Nyberg Jr L, Nickel JC . NIH consensus definition and classification of prostatitis. JAMA 1999; 282: 236–237.
Barry MJ, Fowler Jr FJ, O’Leary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK et al. The American Urological Association Symptom Index for benign prostatic hyperplasia.The Measurement Committee of the American Urological Association. J Urol 1992; 148: 1549–1557.
Litwin MS, McNaughton-Collins M, Fowler Jr FJ, Nickel JC, Calhoun EA, Pontari MA et al. The National Institutes of Health chronic prostatitis symptom index: development and validation of a new outcome measure. Chronic Prostatitis Collaborative Research Network. J Urol 1999; 162: 369–375.
Rosen RC, Cappelleri JC, Smith MD, Lipsky J, Peña BM . Development and evaluation of an abridged, 5-item version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction. Int J Impot Res 1999; 11: 319–326.
McVary K . Lower urinary tract symptoms and sexual dysfunction: epidemiology and pathophysiology. BJU Int 2006; 97: 23–28.
Rosen RC, Wei JT, Althof SE, Seftel AD, Miner M, Perelman MA . Association of sexual dysfunction with lower urinary tract symptoms of BPH and BPH medical therapies: results from the BPH registry. Urology 2009; 73: 562–566.
Ying J, Yao D, Jiang Y, Ren X, Xu M . The positive effect of sildenafil on LUTS from BPH while treating ED. Zhonghua Nan Ke Xue 2004; 10: 681–683.
Roehrborn CG, McVary KT, Elion-Mboussa A, Viktrup L . Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study. J Urol 2008; 180: 1228–1234.
Stief CG, Porst H, Neuser D, Beneke M, Ulbrich E . A randomised, placebo-controlled study to assess the efficacy of twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Eur Urol 2008; 53: 1236–1244.
Liang CZ, Zhang XJ, Hao ZY, Shi HQ, Wang KX . Prevalence of sexual dysfunction in Chinese men with chronic prostatitis. BJU Int 2004; 93: 568–570.
Tuncel A, Akbulut Z, Atan A, Basar MM . Common symptoms in men with prostatic inflammation. Int Urol Nephrol 2006; 38: 583–586.
Turner JA, Hauge S, Von Korff M, Saunders K, Lowe M, Berger R . Primary care and urology patients with the male pelvic pain syndrome: symptoms and quality of life. J Urol 2002; 167: 1768–1773.
Aubin S, Berger RE, Heiman JR, Ciol MA . The association between sexual function, pain, and psychological adaptation of men diagnosed with chronic pelvic pain syndrome type III. J Sex Med 2008; 5: 657–667.
Robert G, Descazeaud A, Nicolaïew N, Terry S, Sirab N, Vacherot F et al. Inflammation in benign prostatic hyperplasia: a 282 patients’ immunohistochemical analysis. Prostate 2009; 69: 1774–1780.
Kramer G, Marberger M . Could inflammation be a key component in the progression of benign prostatic hyperplasia? Curr Opin Urol 2006; 16: 25–29.
Ozden C, Ozdal OL, Guzel O, Han O, Seckin S, Memis A . The correlation between serum prostate specific antigen levels and asymptomatic inflammatory prostatitis. Int Urol Nephrol 2007; 39: 859–863.
Nickel JC, Roehrborn CG, O’Leary MP, Bostwick DG, Somerville MC, Rittmaster RS . The relationship between prostate inflammation and lower urinary tract symptoms: examination of baseline data from the REDUCE trial. Eur Urol 2008; 54: 1379–1384.
Sprague AH, Khalil RA . Inflammatory cytokines in vascular dysfunction and vascular disease. Biochem Pharmacol 2009; 78: 539–552.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Eryildirim, B., Aktas, A., Kuyumcuoglu, U. et al. The effectiveness of sildenafil citrate in patients with erectile dysfunction and lower urinary system symptoms and the significance of asymptomatic inflammatory prostatitis. Int J Impot Res 22, 349–354 (2010). https://doi.org/10.1038/ijir.2010.26
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/ijir.2010.26
Keywords
This article is cited by
-
Prospective Study on Association of Prostatic Calcifications with Clinical Symptoms and Results of Treatment in Men with type III prostatitis
Scientific Reports (2017)
-
The role of phosphodiesterase-5 inhibitors in prostatic inflammation: a review
Journal of Inflammation (2015)
-
Sexual dysfunction in chronic prostatitis/chronic pelvic pain syndrome
World Journal of Urology (2013)